行情

AGTC

AGTC

应用基因科技公司
NASDAQ

实时行情|Nasdaq Last Sale

3.370
+0.170
+5.31%
盘后: 3.370 0 0.00% 18:25 04/08 EDT
开盘
3.250
昨收
3.200
最高
3.430
最低
3.220
成交量
6.89万
成交额
--
52周最高
10.42
52周最低
2.290
市值
8,330.41万
市盈率(TTM)
-3.1789
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGTC价格均价为15.64,最高价位25.00,最低价为7.50。

EPS

AGTC 新闻

更多
  • Applied Genetic Technologies (AGTC) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 1天前
  • All You Need to Know About Applied Genetic Technologies (AGTC) Rating Upgrade to Buy
  • Zacks · 03/24 17:00
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia
  • GlobeNewswire · 03/16 12:00

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

AGTC 简况

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
展开

微牛提供Applied Genetic Technologies Corp(NASDAQ-AGTC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGTC股票新闻,以帮助您做出投资决策。